Cargando…

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence

Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimosiari, Athina, Patoulias, Dimitrios, Kitas, George D., Dimitroulas, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962740/
https://www.ncbi.nlm.nih.gov/pubmed/36835838
http://dx.doi.org/10.3390/jcm12041302
_version_ 1784896080725409792
author Dimosiari, Athina
Patoulias, Dimitrios
Kitas, George D.
Dimitroulas, Theodoros
author_facet Dimosiari, Athina
Patoulias, Dimitrios
Kitas, George D.
Dimitroulas, Theodoros
author_sort Dimosiari, Athina
collection PubMed
description Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the economic burden seems to be unbearable even for developed countries in the Western World. The role of inflammation in the development and progression of CVD appears to be crucial, while, various inflammatory pathways, such as the Nod-like receptor protein 3 (NLRP3) inflammasome-interleukin (IL)-1/IL-6 pathway of the innate immunity, have attracted scientific interest during the last decade, as a potential treatment target in primary and/or secondary prevention of CVD. Whereas there is a significant amount of evidence, stemming mainly from observational studies, concerning the cardiovascular safety of IL-1 and IL-6 antagonists in patients with rheumatic diseases, evidence from relevant randomized controlled trials (RCTs) is rather scarce and conflicting, especially for patients without underlying rheumatic disease. In this review, we summarize and critically present the currently available evidence, both from RCTs and observational studies, concerning the place that IL-1 and IL-6 antagonists may hold in the treatment of CVD.
format Online
Article
Text
id pubmed-9962740
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99627402023-02-26 Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence Dimosiari, Athina Patoulias, Dimitrios Kitas, George D. Dimitroulas, Theodoros J Clin Med Review Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the economic burden seems to be unbearable even for developed countries in the Western World. The role of inflammation in the development and progression of CVD appears to be crucial, while, various inflammatory pathways, such as the Nod-like receptor protein 3 (NLRP3) inflammasome-interleukin (IL)-1/IL-6 pathway of the innate immunity, have attracted scientific interest during the last decade, as a potential treatment target in primary and/or secondary prevention of CVD. Whereas there is a significant amount of evidence, stemming mainly from observational studies, concerning the cardiovascular safety of IL-1 and IL-6 antagonists in patients with rheumatic diseases, evidence from relevant randomized controlled trials (RCTs) is rather scarce and conflicting, especially for patients without underlying rheumatic disease. In this review, we summarize and critically present the currently available evidence, both from RCTs and observational studies, concerning the place that IL-1 and IL-6 antagonists may hold in the treatment of CVD. MDPI 2023-02-06 /pmc/articles/PMC9962740/ /pubmed/36835838 http://dx.doi.org/10.3390/jcm12041302 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dimosiari, Athina
Patoulias, Dimitrios
Kitas, George D.
Dimitroulas, Theodoros
Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
title Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
title_full Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
title_fullStr Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
title_full_unstemmed Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
title_short Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
title_sort do interleukin-1 and interleukin-6 antagonists hold any place in the treatment of atherosclerotic cardiovascular disease and related co-morbidities? an overview of available clinical evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962740/
https://www.ncbi.nlm.nih.gov/pubmed/36835838
http://dx.doi.org/10.3390/jcm12041302
work_keys_str_mv AT dimosiariathina dointerleukin1andinterleukin6antagonistsholdanyplaceinthetreatmentofatheroscleroticcardiovasculardiseaseandrelatedcomorbiditiesanoverviewofavailableclinicalevidence
AT patouliasdimitrios dointerleukin1andinterleukin6antagonistsholdanyplaceinthetreatmentofatheroscleroticcardiovasculardiseaseandrelatedcomorbiditiesanoverviewofavailableclinicalevidence
AT kitasgeorged dointerleukin1andinterleukin6antagonistsholdanyplaceinthetreatmentofatheroscleroticcardiovasculardiseaseandrelatedcomorbiditiesanoverviewofavailableclinicalevidence
AT dimitroulastheodoros dointerleukin1andinterleukin6antagonistsholdanyplaceinthetreatmentofatheroscleroticcardiovasculardiseaseandrelatedcomorbiditiesanoverviewofavailableclinicalevidence